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136Cilostazol inhibits accumulation of triglycerides in
a rat model of carotid artery ligation
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Objective: Triglyceride (TG) accumulation in arterial tissue is associated with the development of cardiovascular disease;
however, the underlying mechanism remains unclear. Cilostazol (CLZ), a selective inhibitor of phosphodiesterase 3, has
antiplatelet and vasodilating effects and may decrease serum TG levels. We examined the effect of CLZ on TG accu-
mulation in the arterial tissue of a rat model of carotid artery ligation.
Methods: Rats were fed normal chow with 0.1% CLZ (CLZ group) or without CLZ (control group) for 4 weeks after
unilateral carotid artery ligation near the carotid bifurcation.
Results: At the end of this period, the control group showed 3.3-fold higher TG levels in the ligated carotid artery than in
the contralateral artery; however, compared with the contralateral artery, the ligated artery in the CLZ group showed
signiﬁcantly lower levels of TG accumulation but similar serum levels of TG, total cholesterol, and high-density lipo-
protein cholesterol. Furthermore, matrix-assisted laser desorption/ionization imaging mass spectrometry revealed that
the ligated carotid artery in both groups had ubiquitous accumulation of TG in the intima, media, and adventitia, along
with decreased heme B signals, which was indicative of ischemia. However, heme B signals were less reduced in the CLZ
group than in the control group.
Conclusions: Our results indicate that CLZ can inhibit the ubiquitous accumulation of TG in arterial tissues, possibly by
ameliorating tissue ischemia. CLZ may be useful in improving arterial tissue hemodynamics and lipid metabolism. (J Vasc
Surg 2013;58:1366-74.)
Clinical Relevance: Triglyceride (TG) accumulation in arterial tissue is associated with the development of cardiovascular
disease; however, the underlying mechanism remains unclear. Cilostazol, an antiplatelet and vasodilating drug, has been
widely used for patients with peripheral artery occlusive disease to improve intermittent claudication. This study exam-
ined the effect of cilostazol on TG accumulation in the arterial tissue of a rat model of carotid artery ligation. We
identiﬁed a novel effect of cilostazol on inhibition of accumulating TG in the ligated carotid artery tissue. This effect may
be expected in clinical use in humansElevated serum levels of triglycerides (TGs) have been
reported to be a more signiﬁcant independent risk factor for
cardiovascular disease than other lipids, such as elevated
serum levels of low-density lipoprotein cholesterol (LDL-C)
or decreased serum levels of high-density lipoprotein
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6are diffusely deposited in vascular tissue such as the coro-
nary artery and myocardium.2-5 The accumulation of TG
is expected to promote the development of cardiovascular
disease, although the exact mechanism has not been fully
elucidated.
Cilostazol (CLZ) is a selective inhibitor of phosphodi-
esterase 3. It increases intracellular cyclic adenosine mono-
phosphate (cAMP) content and activates protein kinase A
(PKA), thereby reducing platelet aggregation and causing
peripheral vasodilation.6,7 CLZ has therefore been used
as a vasodilating antiplatelet drug for the treatment of
ischemic symptoms, such as intermittent claudication in
chronic peripheral arterial obstruction or for the secondary
prevention of brain infarction.6-8 Speciﬁcally, in patients
with intermittent claudication, it improves maximal and
pain-free walking distances.
A recent meta-analysis of randomized control trials
revealed that CLZ may be beneﬁcial in preventing the
progression of carotid atherosclerosis and improving the
proatherogenic lipid proﬁle by decreasing serum TG and
LDL-C levels.9 We hypothesized that CLZ may reduce
the accumulation of TG in arterial intimal hyperplasia and
inhibit it. To demonstrate the hypothesis, we used a rat
model of carotid artery ligation and observed the changes
in TG distribution in the artery.
Fig 1. Schema of carotid artery ligation. The carotid artery on one
side was isolated from the perivascular tissue and ligated near the
carotid bifurcation to stop the blood ﬂow. A 5-mm-long section of
arterial tissue proximal to the ligation was harvested (double arrow).
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The animal care measures and experimental procedures
adopted in this study were approved by the Animal Care
Committee at the Hamamatsu University School of Medi-
cine Animal Care Facility.
Animals and treatment. Male 8-week-old Sprague-
Dawley rats were purchased from SLC (Hamamatsu,
Shizuoka, Japan) and allowed free access to food and
water. The rats were anesthetized with an intraperitoneal
injection of pentobarbital sodium (40 mg/kg; Dainippon
Pharmaceutical, Tokyo, Japan). The rat models of carotid
artery ligation were established as reported in previous
studies.10,11 Brieﬂy, the carotid artery on one side was
isolated from the perivascular tissue and ligated near the
carotid bifurcation to stop blood ﬂow, which induced rapid
proliferation of the medial smooth muscle cells (Fig 1).10
After the treatment, the rats were divided into (1) a
control group (n ¼ 6) that was fed regular chow without
CLZ and (2) a CLZ group (n ¼ 6) that was fed regular
chow containing 0.1% CLZ. The dosage of CLZ used in
this study was adequate for maintaining blood drug
concentrations in rats at approximately the maximum
drug concentration (Cmax) for humans, based on phar-
macokinetic studies in the company’s laboratory (data not
shown).
As previously demonstrated by Kumar et al10 (as
mentioned above), maximum hyperplasia was observed 4
weeks after the carotid artery was ligated. Therefore, the
rats were euthanized 4 weeks after the operation, and
samples of carotid artery on both sides and blood were ob-
tained. No rats were excluded due to premature death or
infection.
Histology and morphometry. For the assessment of
intimal hyperplasia, the rats were transcardially perfused
with 4% paraformaldehyde in phosphate-buffered saline
under physiologic pressure. For the morphometric analysis,
serial 5-mm-thick sections obtained from the region 2 mm
proximal to the ligated site were stained with elastica van
Gieson. Perimeters of the lumen, the internal elastic
lamina, and the external elastic lamina were determined by
tracing the contours on digitized images. The total area of
the intima plus media was determined by subtracting the
lumen area from the area deﬁned by the external elastic
lamina, as described previously.10,11
Measurement of serum lipids and drug concentra-
tion. Blood was collected 4 weeks after the operation, and
serum was obtained by centrifuging it at 2000g for 10
minutes at room temperature. Serum levels of TG, total
cholesterol, free cholesterol ester, phospholipid, and
HDL-C were measured with a multifunction automatic
analyzer system (BiOLis 24i; Tokyo Boeki Machinery Ltd,
Tokyo, Japan). Serum-free cholesterol was measured with
a multiplate reader (Soft MAX Pro, Spectra MAX 190;
Molecular Devices, Sunnyvale, Calif) by using reagents for
the BiOLis 24i. The serum CLZ concentration was
measured using a high-performance liquid chromatography
system (LC-20AD; Shimadzu Corp, Kyoto, Japan).Biochemical quantitation of tissue TG. Total lipids
in tissue were extracted from homogenized tissue by using
the Bligh-Dyer method, as previously described.12,13 The
amount of TG was quantiﬁed using the E-Test Wako lipid
assay kit (Wako Pure Chemical Industries, Osaka, Japan)
based on the enzymatic determination method.14
Imaging mass spectrometry. To visualize the distri-
bution of biomolecules, such as phosphatidylcholine
(PC), heme B, and TG, in the arterial tissue and assess
the accumulated levels of these molecules, we performed
matrix-assisted laser desorptioneionization imaging mass
spectrometry (MALDI-IMS). For MALDI-IMS analysis,
the harvested carotid artery was immediately frozen in
liquid nitrogen and stored at 80C until use. We cut the
frozen tissues into 8-mm-thick longitudinal sections by
using a cryostat (CM1950; Leica, Wetzlar, Germany).
The sections were thaw-mounted onto indium tin
oxide-coated glass slides (Bruker Daltonics, Bremen,
Germany) and dried at room temperature. A total of
Table. Serum levels of lipidsa
Serum lipids
Control (n ¼ 6),
mean 6 SD
Cilostazol (n ¼ 6),
mean 6 SD
TG, mg/dL 70.2 6 7.3 56.4 6 21.3
Cholesterol, mg/dL
Total 58.3 6 6.6 55.8 6 8.7
Free 10.2 6 2.4 9.6 6 2.8
HDL 28.9 6 3.6 28.7 6 5.5
Phospholipid, mg/dL 113.4 6 8.1 107.2 6 13.1
HDL, High-density lipoprotein; SD, standard deviation; TG, triglyceride.
aBlood samples of the rats in the control group and cilostazol group were
collected 4 weeks after the operation, and serum samples were obtained by
centrifuging blood at 2000g for 10 minutes at room temperature. The levels
of TGs, total cholesterol, free cholesterol, phospholipid, and HDL-
cholesterol were measured as serum lipids. Signiﬁcant differences in the
ion intensity ratio among groups were determined by using Tukey-Kramer
test.
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in methanol/water, 7:3, v/v) was sprayed on the sample
sections by using a 0.2-mm nozzle Procon Boy FWA
Platinum airbrush (Mr Hobby, Tokyo, Japan). A 15-cm
distance was maintained between the nozzle and the
tissue surface during spraying. We performed IMS using
a MALDIetime-of-ﬂight (TOF)/TOFetype instrument
(Ultraﬂex II TOF/TOF; Bruker Daltonics) equipped with
a 355-nm neodymium-doped yttrium aluminium garnet
laser with a repetition rate of 200 Hz. The data were
acquired with a step size of 20 mm, in the positive ion
mode (reﬂector mode). The mass spectrometer parameters
were set to obtain the highest sensitivity with m/z values in
the range of 400 to 1000. The laser was used to irradiate
each position 100 times. The peaks were normalized to the
total ion current and then compared. The Flex Imaging
software (Bruker Daltonics) was used for acquiring all the
spectra and for creating the ion images.
Tandem MS. Tandem MS on the tissue sections was
performed by using a linear quadruple ion trap LTQ-XL
mass spectrometer, as described previously.15 Precursor
and fragment ions obtained by collision-induced dissoci-
ation were ejected from the ion trap and analyzed.
Collision energy was set to 30% (this unit is customized for
LTQ-XL; 100% indicates the energy that completely
fragments the peptide methionine-arginine-phenylalanine-
alanine). The laser energy was set to 30 mJ. Speciﬁc frag-
ment patterns of TG, PC, and heme B were conﬁrmed
using data from previous reports. TG is formed by
combining glycerol with three molecules of fatty acid.
Tandem MS analysis enabled identiﬁcation of the TG
species. The fatty acid composition of TG(52:3) and
TG(52:2) is 16:0/18:2/18:1 and 16:0/18:1/18:1,
respectively.16-19
Statistical analysis. Results are summarized using
descriptive statistics. All data are expressed as mean 6
standard deviation, and signiﬁcances of the intergroup
differences were assessed by two-tailed t-test. A value of
P < .05 was considered signiﬁcant. All statistical analyses
were performed using Stat View 5.0 software (SAS Institute,
Tokyo, Japan).RESULTS
Serum level of lipids and CLZ. At 4 weeks after the
operation, we measured the serum levels of TG using
conventional biochemical tests for quantitative assessment
(Table). The results showed no signiﬁcant intergroup
differences in the serum lipid proﬁles of TG, total choles-
terol, free cholesterol, phospholipid, and HDL-C (Table).
The serum CLZ level in the CLZ group was 0.056 6
0.014 mg/mL. The observed level of blood concentration
of CLZ was lower than the Cmax of 0.8 mg/mL for
humans. However, a previous pharmacokinetic study
identiﬁed that the blood concentration of CLZ in the
daytime is low in rats but increases to levels w0.8 mg/mL
from late evening to early morning because rats eat chow
during the night (data not shown).Tissue accumulation of TG. At 4 weeks after the
operation, the analysis of the homogenized tissue samples
in the control group revealed that the TG contents in the
ligated carotid artery were 3.31-fold higher than that in
the contralateral untreated carotid artery (P < .05; Fig 2).
In the CLZ group, however, TG contents in the ligated
carotid artery were 1.90-fold higher than that in the
contralateral untreated carotid artery (P < .05; Fig 2).
Intergroup comparison of the TG contents in the ligated
carotid arteries revealed that the TG contents in the
CLZ group were 50.9% less than that in the control group
(P < .05; Fig 2). However, there was no signiﬁcant inter-
group difference in the TG contents in the contralateral
untreated carotid arteries.
Imaging MS. Five peaks in the mass spectrum patterns
(m/z 616, 782, 798, 879, and 881) of the carotid artery
tissues were selected for investigating the distribution of
the corresponding molecules. According to previous
reports, the peaks corresponded to heme B (which indicates
the level of tissue blood ﬂow), PC(diacyl 16:0/18:1)þNa,
PC(diacyl 16:0/18:1)þK, TG(52:3)þK, and TG(52:2)þ
K (Fig 3, a).20 Fig 3, b shows the representative MALDI-
IMS images of the carotid artery tissues obtained 4 weeks
after the operation. Two-dimensional imaging analysis
of PC(diacyl 16:0/18:1) revealed its ubiquitous distribu-
tion in the arterial walls in both groups; therefore, PC(diacyl
16:0/18:1) was used as an internal standard molecule. The
ligated carotid arteries in both groups showed considerably
decreased heme B distribution and marked accumulation of
TG(52:3)þK and TG(52:2)þK. However, the accumula-
tion of TG(52:3)þK and TG(52:2)þK was much less in the
CLZ-treated group than that in the control group. Further,
the control group showed ubiquitous TG accumulation
in the ligated carotid artery, not only in the intimal
hyperplastic region but also in the media and adventitia of
the artery.
Fig 4 shows quantitative intergroup comparisons of
heme B, TG(52:3), and TG(52:2), expressed as a ratio of
relative intensity (RRI) of MALDI-IMS. RRI was
Fig 2. Triglyceride (TG) content is decreased in the carotid artery
by cilostazol (CLZ). The amount of TGs in the arterial tissue was
quantiﬁed using the colorimetric method. The carotid artery was
harvested 4 weeks after the operation from the rats in the CLZ-
treated group and the control group (n ¼ 6 for each group).
Data are reported as means 6 standard deviation. Signiﬁcant
intergroup differences in the ion intensity ratio were determined
by the Tukey-Kramer test; *P < .05, indicating a signiﬁcant
difference.
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and adventitia in the carotid artery analyzed by IMS
covered the total ion intensities. The ion intensity obtained
from each tissue was not the absolute value; therefore, the
ion intensity of each molecule was standardized to that
of PC(16:0/18:1) and expressed as an RRI because
PC(16:0/18:1) is widely used as the internal standard
molecule at mammalian tissue. No intergroup differences
were noted in the RRI of heme B, TG(52:3), and
TG(52:2) in the contralateral untreated carotid arteries
(n ¼ 6 each group), but the RRI of heme B in the ligated
carotid arteries was smaller than that in the contralateral
untreated carotid artery in both groups. The reduction in
heme B signals in the ligated artery was ameliorated in
the CLZ group compared with the control group. Further,
the accumulation of TG(52:3) and TG(52:2) was greater
in the ligated carotid artery than in the contralateral,
untreated artery in both groups. However, the elevation
in the levels of TG(52:3) and TG(52:2) in the ligatedarteries was smaller in the CLZ group than in the control
group (Fig 4).
Histopathologic examination. Histopathologic ex-
amination using elastica van Gieson staining showed that
the total areas of the intima and media in the ligated carotid
arteries were 4.2-fold and 3.8-fold those in the contralat-
eral carotid arteries in the control group and CLZ group,
respectively (P < .05, both cases; Fig 5). However, the
total area of the intima and media of the ligated carotid
artery in the CLZ group was 25.1% less than that in the
control group (P < .05). No signiﬁcant intergroup differ-
ence was noted in the total area of the intima and media of
the contralateral artery. Similar results were obtained in the
analysis of the intima/media ratio.
Histologic examination of control group samples under
a high-power ﬁeld revealed that the adventitial vasa vasorum
(VV) in the ligated carotid arteries showed an increased
intima-medial area with a compromised luminal area
compared with that in the contralateral untreated carotid
artery in control group (Fig 6). However, there appeared
to be no intergroup differences in the morphology of the
adventitial VV of the ligated carotid arteries.
DISCUSSION
Until recently, it was unclear whether the elevation of
serum TG merely serves as a marker for increased TG-
rich remnant lipoproteins or whether it is a risk factor for
atherosclerosis.21 In the past decade, however, the eleva-
tion of serum TG levels has been reported to be an inde-
pendent risk factor for cardiovascular diseases,22 thereby
suggesting that TGs possibly play an important role in
the development of cardiovascular disease. Although these
etiologic studies have strongly suggested an association
between TG accumulation and atherosclerotic disease,
the biologic mechanisms that underlie the process from
local TG accumulation to the development of atheroscle-
rosis remain to be elucidated. We recently demonstrated
direct evidence of accumulation of TG in arterial tissue har-
vested from patients with peripheral artery occlusive
disease.23 Because intimal hyperplasia is regarded as one
of the processes involved in the development of atheroscle-
rosis, the identiﬁcation of TG accumulation in the rat
model of intimal hyperplasia may suggest the involvement
of TG in developing atherosclerosis.
In this study, we used a carotid artery ligation model
that has been widely used in research on intimal hyperplasia,
an important pathologic process in vascular diseases.24 The
ligated carotid artery showed ubiquitous TG accumulation
4 weeks after the ligation. Several mechanisms of TG depo-
sition in vascular tissue have been previously proposed. In
this study, TG was ubiquitously accumulated in the arterial
tissue (ie, in the intima, media, and adventitia of the ligated
carotid artery), suggesting that TG might exist as lipid
droplets in the cytosol of the arterial tissue. Lipid droplets
are formed at microsomal membranes as primordial drop-
lets with a diameter of 0.1 to 0.4 mm and increase in size
by fusion.25 Lipid droplets can be present in the cytosol
of almost all cells, not only adipocytes but also ﬁbroblasts
Fig 3. Imaging mass spectrometry reveals accumulation of triglycerides (TGs) in the ligated carotid artery tissue.
Combined mass spectra were obtained from the carotid arterial tissue sections with and without ligation and with (þ)
and without () cilostazol (CLZ) treatment. a, Representative mass spectrum patterns of the tissues. Five peaks in the
mass spectrum patterns (m/z 616, 782, 798, 879, and 881) of the carotid artery tissues were selected for investigating
the distribution of the molecules. b, Imaging mass spectrometry and optical images of a frozen section (8 mm).
Distributions of phosphatidylcholine (PC) (diacyl 16:0/18:1), heme B, TG(52:3)þK, and TG(52:2)þK in the
analyzed tissue of the control group (CLZ[]) and the cilostazol group (CLZ[þ]) are shown 4 weeks after the
operation. Scale bar ¼ 5 mm.
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using MALDI-IMS provided evidence that intercellular
TG accumulation was localized to lipid droplets in human
atherosclerotic lesions.23 TGs in the lipid droplets originate
from other lipoproteins or are synthesized directly from free
fatty acids.26 Lipid droplets have been proposed to play
a central role in the inﬂammatory response,27 which may
further link these structures to the development of
atherosclerosis.28
Several studies have investigated the effect of hypoxia
on the augmentation of lipid droplets via the expression
of proteins that bind fatty acid.29,30 Recent studies haveindicated that contents of lipid droplets increase in ischemic
human hearts.31 Mylinis et al32 reported that exposure of
human nonadipocyte origin cells to hypoxia causes TG-
rich lipid droplet accumulation via hypoxia-inducible tran-
scription factor-1emediated cellular metabolism. In the
present study, we found decreased heme B signals in the
atherosclerotic region. Heme B is the most abundant
heme; it is synthesized and distributed in erythroid cells
and hepatocytes, indicating that it can be a more speciﬁc
marker for blood stock than formic acid or iron, so that
it could reﬂect the tissue status of blood ﬂow.20,33 There-
fore, we assayed heme B levels for assessing tissue blood
Fig 4. Contents of heme B (a), triglyceride (TG)(52:3) (b), and TG(52:2) (c). Imaging mass spectrometry reveals
amelioration of heme B decrease and inhibition of TG accumulation in the carotid artery by cilostazol (CLZ). The ion
intensity of each molecule is standardized to that of phosphatidylcholine (PC) (diacyl 16:0/18:1) obtained from the
same sample and expressed as a ratio of relative intensity (RRI) in both groups (n ¼ 6 for each group). Data are
reported as means 6 standard deviation. Signiﬁcance was determined by a two-tailed t-test. *P < .05 indicates
a signiﬁcant difference.
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strating that carotid artery ligation causes blood stasis and
hypoxia.34,35 Thus, under the ischemic conditions in the
ligated carotid artery, the intracellular accumulation of fatty
acids (or fatty acid derivatives) and TG deposits as lipid
droplets21 might be accelerated.
In this study, CLZ inhibited TG accumulation in the
ligated carotid artery without inducing a reduction in the
serum TG levels. Previous studies on animals have indicated
that CLZ can lower serum lipid levels36 and inhibit neoin-
timal formation.37 Ito et al36 recently reported that CLZ
inhibits TG accumulation in the aorta of cholesterol-fed
rabbits. They harvested the rabbit aorta and measured TG
contents in the homogenized tissue. Their results were
consistent with the ﬁndings of previous similar studies,
giving rise to speculation that CLZ might inhibit TG secre-
tion from the liver or increase the activity of lipoprotein-
lipase to decrease serum TG level.38,39 Ito et al36 concluded
that the CLZ-induced reduction in serum TG levels might
account for its inhibitory effect on TG accumulation.
Therefore, we chose a rat model not receiving a high-
cholesterol diet, because if such a model were used, we
would be unable to differentiate whether the effects of
CLZ on the inhibition of intimal hyperplasia were caused
by a reduction in serum lipid levels or by direct inﬂuences
on the local arterial tissues such as anti-inﬂammatory effects
and inhibition of smooth muscle cell growth. The results of
inhibiting TG accumulation without a reduction in the
serum TG levels suggested that the inhibitory effect of
CLZ on TG accumulation in the ligated carotid arterymight be attributable to different mechanisms other than
decreased TG release from the liver or the activation of
serum lipoprotein-lipase.38,39
A previous pharmacokinetics study conﬁrmed that the
doses of CLZ used in this study elevated blood concentra-
tion of CLZ to the levels of human Cmax that might be
expected in clinical practice using this dose; therefore, the
inhibition of TG accumulation in arterial tissues by CLZ
might be expected in humans with this dose.
To clarify other mechanisms by which CLZ may inhibit
TG accumulation, we hypothesized that amelioration of
tissue ischemia by CLZ might account for the inhibition
of TG accumulation. As discussed above, carotid artery
ligation has been reported to cause blood stasis and tissue
hypoxia.35 Because carotid artery ligation caused blood
ﬂow cessation, direct diffusion of oxygen from the arterial
lumen to the arterial tissue may be decreased, leading to
hypoxia. However, arterial ligation is known to hinder
VV blood ﬂow, which also causes arterial tissue hypoxia.34
In our study, histologic examination under a high-power
ﬁeld revealed arteriosclerotic changes in the adventitial
VV, with a compromised luminal area in the ligated carotid
artery. Indeed, MALDI-IMS revealed a reduction in the
distribution of heme B in the ligated carotid artery, indi-
cating tissue ischemia. Moreover, CLZ ameliorated the
reduction in heme B in the tissue. Because CLZ is a selec-
tive inhibitor of phosphodiesterase 3 as well as a vasodilat-
ing antiplatelet drug,8 the vasodilatory effect of CLZ might
contribute to the improved blood supply to the arterial
tissues. A previous study using animal models similar to
Fig 5. Cilostazol (CLZ) inhibits neointimal formation in carotid arteries. a, Representative light photomicrographs of
carotid arteries from the control group (CLZ[]) and CLZ group (CLZ[þ]) obtained using elastica van Gieson
method. Bar ¼ 50 mm. b,Morphometry of the carotid arteries of rats in the control group (CLZ[]) and CLZ group
(CLZ[þ]) 4 weeks after the operation. Intergroup comparison is shown of (b) the total area of the intima plus media
and (c) the thickness ratio of intima/media (n ¼ 6 for each group). Data are reported as means 6 standard deviation.
Signiﬁcance of the intergroup differences in the area was determined by two-tailed t-test; *P < .05 indicates a signif-
icant difference.
Fig 6. Cilostazol (CLZ) inhibits neointimal formation of adventitial vasa vasorum (VV) in carotid arteries. Repre-
sentative light photomicrographs of carotid arteries of rats in the control group (CLZ[]) and CLZ group (CLZ[þ]).
Adventitial VV are observed in high-power ﬁelds by using the elastica van Gieson method. Bar ¼ 100 mm. N, Nerve.
JOURNAL OF VASCULAR SURGERY
1372 Tanaka et al November 2013ours reported a protective effect of CLZ on endothelial
function in a rat model of cerebral artery ligation.40
Considering these ﬁndings together, it is possible that
CLZ ameliorated tissue ischemia by maintaining the VV
blood supply to arterial tissues and inhibiting TG accumu-
lation in the carotid artery ligation model. However, the
limitation of our study is that these ﬁndings were obtainedfrom experiments in rats in a small data set. Therefore,
further study is needed to conﬁrm the similar effects in
human beings.
CONCLUSIONS
The ligation of the carotid artery caused ubiquitous TG
accumulation and decreased the heme B contents in the
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Tanaka et al 1373arterial tissue over 4 weeks. The administration of CLZ
ameliorated this decrease in heme B and inhibited TG
accumulation without reducing serum levels TG levels.
Our results suggest a novel mechanism of action of CLZ
in maintaining blood perfusion in arterial tissues.AUTHOR CONTRIBUTIONS
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